The risk of second cancers after diagnosis of primary thyroid cancer is elevated in thyroid microcarcinomas

Thyroid

Volumn 23, Issue 5, 2013, Pages 575-582

  Kim, Christopher ^a   Bi, Xiaofeng ^a,b   Pan, Dongsheng ^a,c   Chen, Yingtai ^a,b   Carling, Tobias ^d   Ma, Shuangge ^a   Udelsman, Robert ^d   Zhang, Yawei ^a  

^a YALE UNIVERSITY   (United States)

^b PEKING UNION MEDICAL COLLEGE   (China)

^c Gansu Province Tumor Hospital   (China)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BRAIN CANCER; BREAST CANCER; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER RISK; CANCER SIZE; FEMALE; HISTOPATHOLOGY; HUMAN; KIDNEY CANCER; LEUKEMIA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MYELOMA; PRIMARY THYROID CANCER; PRIMARY TUMOR; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; SALIVARY GLAND CANCER; SECOND CANCER; SKIN CANCER; THYROID CANCER;

ADULT; AGED; CARCINOMA; COHORT STUDIES; COMBINED MODALITY THERAPY; EPIDEMIOLOGICAL MONITORING; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; REGISTRIES; RISK; SALIVARY GLAND NEOPLASMS; THYROID NEOPLASMS; TUMOR BURDEN; UNITED STATES;

EID: 84880523850     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2011.0406     Document Type: Article

References (42)

1. Davies L, Welch HG 2006 Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 295:2164-2167.
2. Howlader NNA, Krapcho M, Neyman N, Aminou R, Waldron W, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA, Edwards BK (eds) 2011 SEER Cancer Statistics Review, 1975-2008. National Cancer Institute, Bethesda, MD. Available online at http://seer. cancer. gov/csr/1975-2008 (accessed based on November 2010 SEER data submission, posted to the SEER website, 2011).
3. Briseis A. Kilfoy TZ, Theodore R. Holford, Xuesong Han, Mary H. Ward, Andreas Sjodin, Yaqun Zhang, Yana Bai, Cairong Zhu, Grace L. Guo, Nathaniel Rothman, Yawei Zhang 2009 International patterns and trends in thyroid cancer incidence, 1973-2002. Cancer Causes Control 20: 523-531.
4. Rubino C, Vathaire FD, Dottorini ME, Hall P, Schvartz C, Couette JE, Dondon MG, Abbas MT, Langlois C, Schlumberger M 2003 Second primary malignancies in thyroid cancer patients. Br J Cancer 89:1638-1644.
5. Sandeep TC, Strachan MWJ, Reynolds RM, Brewster DH, Scelo G, Pukkala E, Hemminki K, Anderson A, Tracey E, Friis S, McBride ML, Kee-Seng C, Pompe-Kirn V, Kliewer EV, Tonita JM, Jonasson JG, Martos C, Boffetta P, Brennan P 2006 Second primary cancers in thyroid cancer patients: a multinational record linkage study. J Clin Endocrinol Metab 91:1819-1825.
6. Brown AP, Chen J, Hitchcock YJ, Szabo A, Shrieve DC, Tward JD 2008 The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. J Clin Endocrinol Metab 93:504-515.
7. Zhu C, Zheng T, Kilfoy BA, Han X, Ma S, Ba Y, Bai Y, Wang R, Zhu Y, Zhang Y 2009A birth cohort analysis of the incidence of papillary thyroid cancer in the United States, 1973-2004. Thyroid 19:1061-1066.
8. National Cancer Institute 2011 Surveillance, Epidemiology, and End Results (SEER) Program. Available online at www. seer. cancer. gov (accessed April 25, 2011).
9. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM 2009 Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167-1214.
10. Mazzaferri EL 2006 Managing small thyroid cancers. JAMA 295:2179-2182.
11. Ball DW 2010 Selectively targeting mutant BRAF in thyroid cancer. J Clin Endocrinol Metab 95:60-61.
12. Mazzaferri EL, Kloos RT 2001 Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 86:1447-1463.
13. Hall EJ, Wuu C-S 2003 Radiation-induced second cancers: the impact of 3D-CRT and IMRT. Int J Radiat Oncol Biol Phys 56:83-88.
14. Hall P, Holm LE, Lundell G, Bjelkengren G, Larsson LG, Lindberg S, Tennvall J, Wicklund H, Boice JD Jr 1991 Cancer risks in thyroid cancer patients. Br J Cancer 64:159-163.
15. Sawka AM, Thabane L, Parlea L, Ibrahim-Zada I, Tsang RW, Brierley JD, Straus S, Ezzat S, Goldstein DP 2009 Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis. Thyroid 19:451-457.
16. Chuang SC, Hashibe M, Yu GP, Le AD, Cao W, Hurwitz EL, Rao JY, Neugut AI, Zhang ZF 2006 Radiotherapy for primary thyroid cancer as a risk factor for second primary cancers. Cancer Lett 238:42-52.
17. Xu XG, Bednarz B, Paganetti H 2008A review of dosimetry studies on external-beam radiation treatment with respect to second cancer induction. Phys Med Biol 53: R193-241.
18. Brierley JD, Tsang RW 1999 External-beam radiation therapy in the treatment of differentiated thyroid cancer. Semin Surg Oncol 16:42-49.
19. Ronckers CM, McCarron P, Ron E 2005 Thyroid cancer and multiple primary tumors in the SEER cancer registries. Int J Cancer 117:281-288.
20. Subramanian S, Goldstein DP, Parlea L, Thabane L, Ezzat S, Ibrahim-Zada I, Straus S, Brierley JD, Tsang RW, Gafni A, Rotstein L, Sawka AM 2007 Second primary malignancy risk in thyroid cancer survivors: a systematic review and metaanalysis. Thyroid 17:1277-1288.
21. Gudmundsson J, Sulem P, Gudbjartsson DF, Jonasson JG, Sigurdsson A, Bergthorsson JT, He H, Blondal T, Geller F, Jakobsdottir M, Magnusdottir DN, Matthiasdottir S, Stacey SN, Skarphedinsson OB, Helgadottir H, Li W, Nagy R, Aguillo E, Faure E, Prats E, Saez B, Martinez M, Eyjolfsson GI, Bjornsdottir US, Holm H, Kristjansson K, Frigge ML, Kristvinsson H, Gulcher JR, Jonsson T, Rafnar T, Hjartarsson H, Mayordomo JI, de la Chapelle A, Hrafnkelsson J, Thorsteinsdottir U, Kong A, Stefansson K 2009 Common variants on 9q22. 33 and 14q13. 3 predispose to thyroid cancer in European populations. Nat Genet 41:460-464.
22. Kouniavsky G, Zeiger MA 2010 Thyroid tumorigenesis and molecular markers in thyroid cancer. Curr Opin Oncol 22:23-29.
23. Cybulski C, Huzarski T, Gorski B, Masojc B, Mierzejewski M, Debniak T, Gliniewicz B, Matyjasik J, Zlowocka E, Kurzawski G, Sikorski A, Posmyk M, Szwiec M, Czajka R, Narod SA, Lubinski J 2004 Novel founder CHEK2 mutation is associated with increased prostate cancer risk. Cancer Res 64:2677-2679.
24. Cybulski C, Gorski B, Huzarski T, Masojc B, Mierzejewski M, Debniak T, Teodorczyk U, Byrski T, Gronwald J, Matyjasik J, Zlowocka E, Lenner M, Grabowska E, Nej K, Castaneda J, Medrek K, Szymanska A, Szymanska J, Kurzawski G, Suchy J, Oszurek O, Witek A, Narod SA, Lubinski J 2004 CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet 75:1131-1135.
25. Magklara A, Scorilas A, Stephan C, Kristiansen GO, Hauptmann S, Jung K, Diamandis EP 2000 Decreased concentrations of prostate-specific antigen and human glandular kallikrein 2 in malignant versus nonmalignant prostatic tissue. Urology 56:527-532.
26. Slater M, Danieletto S, Gidley-Baird A, Teh LC, Barden JA 2004 Early prostate cancer detected using expression of nonfunctional cytolytic P2X(7) receptors. Histopathology 44:206-215.
27. Paradis V, Dargere D, Laurendeau I, Benoit G, Vidaud M, Jardin A, Bedossa P 1999 Expression of the RNA component of human telomerase (hTR) in prostate cancer, prostatic intraepithelial neoplasia, and normal prostate tissue. J Pathol 189:213-218.
28. Koch CA, Brouwers FM, Vortmeyer AO, Tannapfel A, Libutti SK, Zhuang Z, Pacak K, Neumann HP, Paschke R 2006 Somatic VHL gene alterations in MEN2-associated medullary thyroid carcinoma. BMC Cancer 6:131.
29. Wasenius VM, Hemmer S, Karjalainen-Lindsberg ML, Nupponen NN, Franssila K, Joensuu H 2005 MET receptor tyrosine kinase sequence alterations in differentiated thyroid carcinoma. Am J Surg Pathol 29:544-549.
30. Montani M, Schmitt AM, Schmid S, Locher T, Saremaslani P, Heitz PU, Komminoth P, Perren A 2005 No mutations but an increased frequency of SDHx polymorphisms in patients with sporadic and familial medullary thyroid carcinoma. Endocr Relat Cancer 12:1011-1016.
31. Linehan WM, Srinivasan R, Schmidt LS 2010 The genetic basis of kidney cancer: a metabolic disease. Nat Rev Urol 7:277-285.
32. Roos A, Bakker SJL, Links TP, Gans ROB, Wolffenbuttel BHR 2007 Thyroid function is associated with components of the metabolic syndrome in euthyroid subjects. J Clin Endocrinol Metab 92:491-496.
33. Nikiforov YE, Fagin, J. A 1997 Risk factors for thyroid cancer. Trends Endocrinol Metab 8:20-25.
34. Barzon L, Scaroni C, Sonino N, Fallo F, Paoletta A, Boscaro M 1999 Risk factors and long-term follow-up of adrenal incidentalomas. J Clin Endocrinol Metab 84:520-526.
35. Mellemgaard A, From G, Jorgensen T, Johansen C, Olsen JH, Perrild H 1998 Cancer risk in individuals with benign thyroid disorders. Thyroid 8:751-754.
36. Hellevik AI, Asvold BO, Bjoro T, Romundstad PR, Nilsen TI, Vatten LJ 2009 Thyroid function and cancer risk: a prospective population study. Cancer Epidemiol Biomarkers Prev 18:570-574.
37. Lee SL 2010 Complications of radioactive iodine treatment of thyroid carcinoma. J Natl Compr Canc Netw 8:1277-1286; quiz 1287.
38. Boas M, Main KM, Feldt-Rasmussen U 2009 Environmental chemicals and thyroid function: an update. Curr Opin Endocrinol Diabetes Obes 16:385-391.
39. Gauthier LT, Hebert CE, Weseloh DV, Letcher RJ 2008 Dramatic changes in the temporal trends of polybrominated diphenyl ethers (PBDEs) in herring gull eggs fromthe Laurentian Great Lakes: 1982-2006. Environ Sci Technol 42:1524-1530.
40. Cole P, Trichopoulos D, Pastides H, Starr T, Mandel JS 2003 Dioxin and cancer: a critical review. Regul Toxicol Pharmacol 38:378-388.
41. Negri E, Bosetti C, Fattore E, La Vecchia C 2003 Environmental exposure to polychlorinated biphenyls (PCBs) and breast cancer: a systematic review of the epidemiological evidence. Eur J Cancer Prev 12:509-516.
42. Zhang Y, Guo GL, Han X, Zhu C, Kilfoy BA, Zhu Y, Boyle P, Zheng T 2008 Do polybrominated diphenyl ethers (PBDEs) increase the risk of thyroid cancer?. Biosci Hypotheses 1: 195-199.